AZN:Phase III Trial Of Sipavibart Met Main Goal In Preventing COVID-19 In Immunocompromised Patients

view original post

Sipavibart (formerly AZD3152) is an investigational long-acting monoclonal antibody against COVID-19. Sipavibart was designed to provide broad and potent coverage across Omicron and ancestral viral …